IMD 0354 (CAS 978-62-1)

IMD 0354, an organic compound, has garnered significant attention in scientific research due to its potential applications. This cell-permeable salicylamide compound has demonstrated selective inhibition of IKK β (IKK-2), as observed by blocking IκBα phosphorylation and impeding the nuclear translocation of NF-κB p65. Its efficacy as a cardioprotectant has been highlighted through its ability to decrease IL-1β and MCP-1 production in cardiac muscle cells. Additionally, IMD 0354 exhibits positive effects on insulin resistance regulation by influencing the release of adiponectin in KKAγ mice. Furthermore, IMD 0354 has demonstrated pharmacodynamic effects by inhibiting the synthesis of prostaglandins and nitric oxide, pivotal mediators of inflammation. Moreover, it functions as a potent and selective inhibitor of cyclooxygenase-2 (COX-2), binding to the enzyme′s active site and hindering its activity. Overall, the compound′s broad spectrum of biological activities encompasses anti-inflammatory, anti-cancer, and anti-bacterial effects.